On the stock market since 1981, it operates in the world of health and science. It has 142 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (1% a year). Red columns mark years that ended in a loss.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 87% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $47.50 per share each year — regular cash for whoever holds the stock.
A loss of $0 against $45.3M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.17. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, TLGT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TLGT is a small company that closed last year at a loss. The road back to profit runs through spending discipline.